NDA 050740 · Astellas
Ambisome
Amphotericin B · Injection
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Aug 11, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
171
57 Phase 3, 12 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 2000 Supplement 2 · Efficacy ReviewLetterLabel
- Jan 28, 2000 Supplement 1 · Efficacy ReviewLetterLabel
- Aug 11, 1997 Original approval · Type 2 - New Active Ingredient · priority review Review
1 products under this application
- AMBISOME · AMPHOTERICIN B 50MG/VIAL · INJECTABLE, LIPOSOMAL, INJECTION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amphotericin B" as an intervention, any sponsor and status, largest first.
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)Pivotal-lookingRecruiting
David BoulwareAcademic, hospital or other
NCT06666322 · 2,000 participants (planned) · Start May 28, 2025 · Primary completion Apr 21, 2032
Drug: Standard of care; Oteseconazole - antifungal therapy 1 and 3 more · For: Hiv; Cryptococcal Meningitis
Sites: Kampala, Uganda; Mbarara, Uganda
- Amphotericin B Treatment in Visceral LeishmaniasisPivotal-lookingCompleted
Banaras Hindu UniversityAcademic, hospital or other
NCT00310505 · 1,500 participants · Start Jan 2003
Drug: Amphotericin B deoxycholate given as daily administration · For: Visceral Leishmaniasis
Sites: Muzaffarpur, India
Banaras Hindu UniversityAcademic, hospital or other
NCT01566552 · 1,300 participants (planned) · Start Jun 2014 · Primary completion Dec 2016
Drug: AMBISOME · For: Visceral Leishmaniasis
Sites: Muzaffarpur, India
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)Pivotal-lookingNot yet recruiting
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT07463040 · 900 participants (planned) · Start Jan 1, 2027 · Primary completion Mar 1, 2029
Drug: Sodium Stibogluconate (SSG); Miltefosine and 3 more · For: Cutaneous Leihmaniasis
Sites: Addis Ababa, Ethiopia; Arba Minch, Ethiopia; Boru, Ethiopia
- Perioperative SDD to Prevent Infectious Complications After EsophagectomyPivotal-lookingRecruiting
Radboud University Medical CenterAcademic, hospital or other
NCT05865743 · 854 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2027
Drug: SDD · For: Esophageal Cancer
Sites: Leuven, Belgium; Nijmegen, Netherlands
- Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial TreatmentPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00158730 · 800 participants · Start Apr 2003
Drug: AmBisome · For: Invasive Aspergillosis; Other Fungal Infections
- Safety and Efficacy Study of Paromomycin to Treat Visceral LeishmaniasisPivotal-lookingCompleted
PATHAcademic, hospital or other
NCT00216346 · 667 participants · Start Jun 2003
Drug: Paromomycin sulfate; Amphotericin B · For: Visceral Leishmaniasis
Sites: Agam Kuan, Patna, India; Brahmpura, Muzaffarpur, India; Patna, India · 4 sites in all
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)Pivotal-lookingNot yet recruiting
University of MinnesotaAcademic, hospital or other
NCT07261150 · 664 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2030
Drug: LAmB B; Posaconazole and 2 more · For: Histoplasmosis
Sites: Minneapolis, Minnesota; Porto Alegre, Brazil
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ambisome (Amphotericin B Liposome)
2024 spending
$939K
Beneficiaries
85
325 claims
Per beneficiary
$11,044
$199.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,682,797 |
| 2021 | $1,974,073 |
| 2022 | $2,022,792 |
| 2023 | $1,411,630 |
| 2024 | $938,712 |
Part B: AmbIsome* (Amphotericin B Liposome*) · HCPCS J0289
2024 spending
$1.8M
Beneficiaries
205
1,088 claims
Per beneficiary
$8,816
2024 ASP limit $24.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,559,495 |
| 2021 | $2,315,052 |
| 2022 | $2,333,221 |
| 2023 | $1,748,170 |
| 2024 | $1,807,246 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Jarvis JN, Lawrence DS, Meya DB, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Equivalence Trial
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial.
Boulware DR, Atukunda M, Kagimu E, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
Javandoust Gharehbagh F, Roshanzamiri S, Farjami M, et al. · J Oncol Pharm Pract 2024 · Systematic Review, Meta-Analysis
- Treating progressive disseminated histoplasmosis in people living with HIV.
Murray M, Hine P · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, et al. · N Engl J Med 2002 · Clinical Trial, Comparative Study
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.